ResMed (RMD) Getting Somewhat Positive Media Coverage, Analysis Finds

News headlines about ResMed (NYSE:RMD) have trended somewhat positive on Monday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ResMed earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 45.054390229237 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news articles that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

Several research firms have recently weighed in on RMD. William Blair reissued an “outperform” rating on shares of ResMed in a research report on Monday, April 16th. Zacks Investment Research raised ResMed from a “hold” rating to a “buy” rating and set a $112.00 target price on the stock in a research report on Friday, February 2nd. Citigroup downgraded ResMed from a “buy” rating to a “neutral” rating in a research report on Wednesday, April 4th. Needham & Company LLC reissued a “hold” rating on shares of ResMed in a research report on Wednesday, March 7th. Finally, ValuEngine raised ResMed from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company’s stock. ResMed presently has a consensus rating of “Hold” and an average target price of $74.83.

RMD traded down $0.86 during trading hours on Monday, reaching $97.94. 874,972 shares of the company’s stock traded hands, compared to its average volume of 699,330. ResMed has a 52-week low of $67.04 and a 52-week high of $104.78. The stock has a market cap of $14,121.20, a P/E ratio of 34.73 and a beta of 0.90.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.22. ResMed had a return on equity of 22.75% and a net margin of 12.98%. The company had revenue of $601.27 million during the quarter, compared to analysts’ expectations of $583.77 million. During the same quarter in the previous year, the business earned $0.73 EPS. ResMed’s revenue was up 13.4% compared to the same quarter last year. sell-side analysts anticipate that ResMed will post 3.38 EPS for the current fiscal year.

In related news, insider James Hollingshead sold 600 shares of the business’s stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $98.19, for a total transaction of $58,914.00. Following the completion of the transaction, the insider now owns 59,940 shares in the company, valued at approximately $5,885,508.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Richard Mchale sold 2,000 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $100.12, for a total value of $200,240.00. Following the transaction, the insider now owns 62,002 shares of the company’s stock, valued at approximately $6,207,640.24. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,889 shares of company stock valued at $4,696,386. 1.77% of the stock is owned by company insiders.

WARNING: “ResMed (RMD) Getting Somewhat Positive Media Coverage, Analysis Finds” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/23/resmed-rmd-getting-somewhat-positive-media-coverage-analysis-finds.html.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply